Examkin

Soru

Zorluk: ZorEnd-of-Life and Palliative Care

A 54-year-old woman is admitted to an inpatient hospice facility for the management of intractable symptoms secondary to terminal metastatic cervical cancer. Her clinical course is complicated by a malignant bowel obstruction, rendering her completely intolerant to enteral intake. Over the past 48 hours, she has experienced relentless nausea, frequent large-volume emesis, and diffuse abdominal pain. These symptoms have persisted despite maximally tolerated continuous intravenous infusions of hydromorphone, haloperidol, and octreotide, as well as scheduled intravenous dexamethasone. On examination, the patient is cachectic, visibly distressed, crying, and writhing in bed. Her estimated prognosis is hours to a few days. During the bedside evaluation, the patient clearly states, "I cannot take this agony anymore. Please just put me to sleep so I do not have to suffer until the end." The physician assesses that the patient fully understands her condition and the consequences of her request. Which of the following is the most appropriate next step in management?

  1. Initiate a continuous intravenous infusion of midazolamCevap
  2. B
    Escalate the continuous hydromorphone infusion until the patient is unconscious
  3. C
    Discharge the patient to home hospice for ongoing symptom management
  4. D
    Defer the request until a judge officially determines the patient's legal competence
  5. E
    Administer sublingual buprenorphine to provide adjunctive, synergistic analgesia

Cevap

The most appropriate next step is to initiate a continuous intravenous infusion of midazolam to provide proportionate palliative sedation.
The correct action addresses the patient's refractory suffering through proportionate palliative sedation. When a patient nearing the end of life (prognosis of days to weeks) experiences intractable symptoms that cannot be controlled with aggressive symptom-directed therapies, it is ethically and medically appropriate to reduce their level of consciousness to relieve suffering. This relies on the ethical principle of double effect. Midazolam, a short-acting benzodiazepine, is the first-line agent for this purpose because it reliably provides sedation and amnesia.

Adım Adım Çözüm

1
Evaluate the patient's symptom burden and prognosis.
The patient has refractory pain and vomiting from a malignant bowel obstruction despite maximal medical therapy, with a prognosis of hours to days.
Establishing the presence of refractory terminal symptoms and a short prognosis is required to consider palliative sedation.
2
Assess the patient's decision-making capacity and request.
The patient clearly understands her condition and requests to be "put to sleep" to escape suffering.
Informed consent from a capacitated patient (or their surrogate) is necessary to initiate sedation.
3
Select the appropriate pharmacologic agent for palliative sedation.
A sedative-hypnotic agent, typically a benzodiazepine like midazolam, is selected.
Midazolam reliably induces sedation and amnesia, fulfilling the ethical principle of double effect to relieve intractable suffering at the end of life.

Anahtar Kavram

Proportionate palliative sedation using sedative-hypnotics is indicated for patients with refractory symptoms and a prognosis of less than two weeks, provided there is informed consent.
Tahmini Süre:1m 30s
Bu soruyu puanla

Konular

End-of-Life and Palliative Care

Bu konudan daha fazla soru